Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.44 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | FPR1 | P21462 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21773025 | 0.78 | ADORA1 (0.41) | ADORA1TMIGD3MAPTALDH1A1RAB9A | |
| SCHEMBL2678119 | 0.75 | ADORA1 (0.46) | ADORA1TMIGD3MAPTALDH1A1RAB9A | |
| SCHEMBL29102723 | 0.74 | MAPT (0.42) | ADORA1TMIGD3MAPTALDH1A1RAB9A | |
| SCHEMBL9094362 | 0.73 | MAPT (0.38) | ADORA1TMIGD3MAPTALDH1A1RAB9A | |
| SCHEMBL28803193 | 0.71 | ADORA1 (0.43) | ADORA1TMIGD3MAPTALDH1A1RAB9A | |
| SCHEMBL7382979 | 0.71 | ALDH1A1 (0.50) | ADORA1TMIGD3MAPTALDH1A1RAB9A | |
| SCHEMBL3464550 | 0.71 | GRM5 (0.33) | LMNAHDAC3HDAC1HDAC6 | |
| SCHEMBL4333582 | 0.71 | SMN1; SMN2 (0.43) | MAPTRAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL10328699 | 0.69 | ADORA1 (0.47) | ADORA1TMIGD3MAPTALDH1A1RAB9A | |
| SCHEMBL4769460 | 0.69 | TMIGD3 (0.41) | ADORA1TMIGD3MAPTALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148440-A1 | SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2018-05-31 | — | — | US | disclosed |
| US-20170037042-A1 | SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-02-09 | — | — | US | disclosed |
| EP-2755970-B1 | SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-03-30 | — | — | EP | disclosed |
| US-20150087648-A1 | SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2015-03-26 | — | — | US | disclosed |
| US-8912224-B2 | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals | SANOFI (FR) | 2014-12-16 | — | — | US | disclosed |
| EP-2567958-B1 | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals | SANOFI SA (FR) | 2014-10-29 | — | — | EP | disclosed |
| US-20140243292-A1 | SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-08-28 | — | — | US | disclosed |
| US-20130065859-A1 | SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-03-14 | — | — | US | disclosed |
| EP-2567958-A1 | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals | SANOFI (FR) | 2013-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148440-A1 | SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | RYR2, SLC8B1, P2RX1 | ADORA1 237/4885TMIGD3 2408/4885MAPT 2325/4885 |
| US-20140243292-A1 | SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | RYR2, CACNA1E, SLC8B1 | ADORA1 333/4885TMIGD3 2844/4885MAPT 2286/4885 |
| US-20130065859-A1 | SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | RYR2, SLC8B1, RYR1 | ADORA1 202/4885TMIGD3 2158/4885MAPT 2466/4885 |
| US-20170037042-A1 | SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | RYR2, SLC8B1, P2RX1 | ADORA1 237/4885TMIGD3 2408/4885MAPT 2325/4885 |
| US-20150087648-A1 | SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | RYR2, CACNA1E, SLC8B1 | ADORA1 333/4885TMIGD3 2844/4885MAPT 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.